ClinicalTrials.gg
TerminatedNCT00766337EMERALDUpdated Jan 10, 2013

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

A Phase 2 interventional study of Sirolimus in combination with ranibizumab and Sirolimus in combination with ranibizumab in Age-Related Macular Degeneration and Choroidal Neovascularization, sponsored by Santen Inc.. Terminated at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-01-10.

Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
63rd of 124
62 · median 64
Started
2008
with 10 others
Phase 2
24 of 125
1 open now
Registered
39th of 125
by date
Lead sponsor
2 of 125
Santen Inc.

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 63rd largest by enrollment of the 124 interventional ones that give a count, is one of 11 that started in 2008, is one of 24 in phase 2, and was the 39th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.

03

Conditions studied

  • Age-Related Macular Degeneration
  • Choroidal Neovascularization

Keywords

  • wet AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration within six months of initial study visit, and may have been treated with up to 3 Lucentis® (ranibizumab) or 3 Avastin® (bevacizumab) injections with the last injection administered at least 4 weeks prior to the initial study visit, or is treatment-naïve
  • Visual acuity of 20/40 to 20/200 in the study eye

Exclusion criteria

Exclusion Criteria:

  • Any other ocular disease that could compromise vision in the study eye
  • Presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Dose Group 1

    Drug: Sirolimus in combination with ranibizumab

  • Experimental
    Dose Group 2

    Drug: Sirolimus in combination with ranibizumab

  • Placebo comparator
    Dose Group 3

    Drug: Placebo in combination with ranibizumab

Interventions

  • DrugSirolimus in combination with ranibizumab

    Drug pages: Sirolimus · Ranibizumab

    Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.

    Also known as: MS-R001, rapamycin, Lucentis

  • DrugSirolimus in combination with ranibizumab

    Drug pages: Sirolimus · Ranibizumab

    Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.

    Also known as: MS-R002, rapamycin, Lucentis

  • DrugPlacebo in combination with ranibizumab

    Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.

    Also known as: vehicle, Lucentis

06

What researchers measure

Primary outcomes

  1. Best-corrected visual acuity by ETDRS

    Time frame: 120 days

Secondary outcomes

  1. Retinal thickness

    Time frame: 120 days

  2. Safety across treatment groups

    Time frame: Through 2 years

07

Study locations

1 site
  • Retinal Consultants of Arizona
    Phoenix, Arizona 85014, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Nov 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2008
First posted
Oct 3, 2008
Start
Dec 2008
Primary completionActual
Nov 2009
CompletionActual
Mar 2010
Last update
Jan 10, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00766337
Lead sponsor
Santen Inc.
Collaborators
MacuSight, Inc.
Responsible party
Sponsor
First posted
Oct 3, 2008
Start date
Dec 2008
Primary completion
Nov 2009
Completion
Mar 2010
Last update
Jan 10, 2013

Study contacts

Joel Naor, MD
study director · MacuSight, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sirolimus · Ranibizumab

Start the discussion